TITLE

Biotech M&A hits target

AUTHOR(S)
Cheok Soh Hui
PUB. DATE
May 2007
SOURCE
ICIS Chemical Business;5/14/2007, Vol. 2 Issue 66, p12
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on the mergers and acquisitions (M&A) in Asia's biotechnology industry. Eisai Co. plans to buy Morphoteck, while Takeda Pharmaceuticals plans to acquire Paradigm. It is observed that the mergers by Asian firms could fuel greater competition in the global biotechnology M&A activity. It is reported that India is expanding in active pharmaceutical ingredients (API) and generic drugs manufacturing, while Japan is encouraging investment in generics manufacturing.
ACCESSION #
25393702

 

Related Articles

  • Genesis of an industry.  // New Scientist;10/26/2002, Vol. 176 Issue 2366, p56 

    Analyzes prospects for the biotechnology industry in the U.S. Relevance of genomics in drug development; Business models developed by several genomics companies; Consolidation between firms with similar businesses in the industry.

  • Past is Prologue. Hoffman, Michelle // Drug Discovery & Development;Aug2006, Vol. 9 Issue 8, p4 

    The author reflects on the science, art, and business of drug discovery and development in the U.S. She provides insights into the merger between biotechnology firm Genentech and Roche, a pharmaceutical company. The author also discusses the access of pharmaceutical firms to novel compounds and...

  • The History of Drug Development (pt. 1). Snyder, Steve // Contract Pharma;Apr2011, Vol. 13 Issue 3, p30 

    The article offers the author's insights on the history of drug development. He mentions that the pharmaceutical industry was threatened by the generic drug sector which uses patent expiration, and that the pharmaceutical industry needed outsourcing services such as contract research...

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;May2006, Vol. 5 Issue 5, p3 

    The article offers news briefs in the pharmaceutical industry. Controversy has surrounded drug development in Great Britain after several men suffered severe reactions in a clinical trial of an investigational anti-inflammatory drug. Amagen Technologies has completed its acquisition of fellow...

  • Then and now. Verma, Inder // Nature;7/28/2005, Vol. 436 Issue 7050, p478 

    Focuses on the success of the biotechnology industry in India. Details on the desire of the biotechnology and pharmaceutical industry to undertake novel challenges; Rank of the country as provider of generic drugs in the world; Need for the Indian government to reduce the bureaucracy required...

  • Licensing Trends in Pharma and Biotech. McCubbin, Paul // Pharmaceutical Licensing: Deal Sourcing & Metrics;2007, p5 

    The article looks into the licensing trends in the pharmaceutical and biotechnology industry and their implications on the leading companies' commitment to biological drug development in Europe. It says that the operational strategy of pharmaceutical companies has led to an increase in...

  • Anticipating the Aftermath of M&As. Getz, Kenneth A. // Applied Clinical Trials;Sep2009, Vol. 18 Issue 9, p28 

    The article focuses on the increase of merger and acquisition (M&A) activity among pharmaceutical and biotechnology companies which is strong and potentially will continue through 2010. However, it mentions that the practice of mergers and acquisitions seem to either fall short of anticipations...

  • Upsher-Smith Nabs Proximagen In CVR-Based $555M Buyout. Moran, Nuala // BioWorld International;6/20/2012, Vol. 17 Issue 25, p3 

    The article reports on the acquisition of Proximagen Group plc by Upsher-Smith Laboratories Ltd., worth 356.8 million pounds. Having 10 Proximagen programs in clinical development, Upsher-Smith is basically buying an early stage Research and Development engine to incorporate to its clinical...

  • OTHER NEWS TO NOTE.  // BioWorld International;11/28/2007, Vol. 12 Issue 48, p3 

    This section offers news briefs related to the biotechnology industry. A lead candidate was chosen by Argenta Discovery Ltd. and Dr. Reddy's Laboratories Inc. in their program to develop an inhaled, disease-modifying, anti-inflammatory drug for chronic respiratory diseases. Eurofins Scientific...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics